Sio Feng
Family · Campbell, CANPI 1245778513
Payments from drug & device makers
Across 381 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$863
- Amgen$810
- AstraZeneca$728
- Xeris Pharmaceuticals, Inc.$630
- Lilly USA, LLC$446
- plus $4K from 42 others
What the payments were for
- Food & beverage$8,923100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,935 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 200 | $336,685 |
| JardianceEmpagliflozin | 211 | $245,231 |
| Teriparatide | 25 | $57,775 |
| RybelsusSemaglutide | 31 | $57,714 |
| TrulicityDulaglutide | 30 | $45,947 |
| FarxigaDapagliflozin Propanediol | 32 | $40,249 |
| KerendiaFinerenone | 26 | $38,954 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $33,446 |
| MounjaroTirzepatide | 19 | $33,342 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $11,683 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $10,208 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 68 | $9,817 |
| Gvoke Hypopen 2-PackGlucagon | 16 | $9,738 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 23 | $7,360 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,177 | $394,399231 claims |
| Boehringer IngelheimJardiance | $202 | $245,231211 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $446 | $79,28949 claims |
| AstraZenecaFarxiga | $728 | $40,24932 claims |
| BayerKerendia | $400 | $38,95426 claims |
| AbbVieSynthroid | $374 | $1,00011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Campbell
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.